Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The endocrine effects of 125 mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125 mg AG + 20 mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG + HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG + HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.

Original publication

DOI

10.1038/bjc.1985.223

Type

Journal article

Journal

Br J Cancer

Publication Date

10/1985

Volume

52

Pages

525 - 529

Keywords

Adult, Aged, Aminoglutethimide, Androstenedione, Breast Neoplasms, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Depression, Chemical, Drug Combinations, Estradiol, Estrone, Female, Humans, Hydrocortisone, Menopause, Middle Aged, Time Factors